Adaptive Biotechnologies Corp
Company Profile
Business description
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.
Contact
1165 Eastlake Avenue East
SeattleWA98109
USAT: +1 206 659-0067
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 December 2026
Employees
624
Stocks News & Analysis
stocks
Margins have bottomed for ASX listed consumer goods company
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,997.20 | 52.50 | -0.58% |
| CAC 40 | 8,400.11 | 21.03 | -0.25% |
| DAX 40 | 25,139.69 | 153.87 | 0.62% |
| Dow JONES (US) | 51,712.71 | 148.01 | 0.29% |
| FTSE 100 | 10,437.85 | 74.58 | 0.72% |
| HKSE | 23,499.88 | 268.64 | -1.13% |
| NASDAQ | 26,166.60 | 351.33 | -1.32% |
| Nikkei 225 | 71,090.99 | 1,262.97 | -1.75% |
| NZX 50 Index | 13,414.15 | 31.90 | -0.24% |
| S&P 500 | 7,472.79 | 27.79 | -0.37% |
| S&P/ASX 200 | 8,794.10 | 41.00 | -0.46% |
| SSE Composite Index | 4,147.55 | 15.55 | -0.37% |